FDA’s peptide plans reinforce concerns about ideology, politics influencing its decisions

Responding to HHS Secretary Robert F. Kennedy Jr.’s enthusiasm for peptides, FDA has started a process that could remove a dozen compounds from its list of substances barred from bulk compounding. The agency will convene a July advisory committee meeting to consider allowing their broader, largely unregulated use.

Although FDA will consider permitting these products to be marketed for conditions ranging from ulcerative colitis and wound healing to obesity, insomnia, and neurological disorders, there is little or no robust clinical evidence supporting their safety or effectiveness. ...